newsfilter
← Latest News
GlobeNewswire·

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized